María González Cao

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Luping Lin, Amit J. Sabnis, Elton Chan et al. · Nature Genetics · 2015 · 548 citations · Full text

Medicine, Mek-targeted Cancer Therapies, Hippo Effector Yap +8

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 78 citations · Full text

Nivolumab Versus Docetaxel, Medicine, Pharmacology +7

Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma

Roniel Cabrera, Miguel Ararat, Erika A. Eksioglu et al. · Scandinavian Journal of Immunology · 2010 · 41 citations · Full text

Soluble Cd25, T-regulatory Cell, Immunology +19

Lung cancer patients with COVID-19 in Spain: GRAVID study

Mariano Provencio, José María Mazarico Gallego, Antonio Calles et al. · Lung Cancer · 2021 · 39 citations · Full text